Digital therapeutics platform Kaiku Health and Novartis are expanding on their precision med partnership, the companies announced this week.
Last year, Kaiku shared the news that the companies would be jointly developing a therapy-specific module for patients receiving Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adjuvant, unresectable or metastatic melanoma with BRAF mutation. The companies sought to gain insights into real-world patient outcomes that would aid in creating advanced machine learning-based algorithms, like symptom prediction.
Kaiku Health’s deputy general manager and co-founder Henri Virtanen said that the next phase of the partnership will focus on enhancing now existing mL-models in melanoma but also starting to work on similar models for other indications and treatments.